论文部分内容阅读
目的探讨喹硫平治疗儿童精神分裂症的疗效、安全性及依从性。方法 79例儿童精神分裂症患者随机分为两组,分别予以喹硫平和利培酮治疗8周。采用简明精神病评定量表(BPRS)、副反应量表(TESS)在治疗前及治疗第2、4、8周末分别评定疗效与不良反应,并于16周后随诊或电话随访调查。结果 TESS治疗组显效率为82.50%,总有效率为95.00%;对照组显效率为82.05%,总有效率为92.30%,两组显效率、总有效率比较无明显差异(U=0.16,P>0.05)。结论喹硫平与利培酮治疗儿童精神分裂症疗效相仿,而喹硫平组依从性好于利培酮组。
Objective To investigate the efficacy, safety and compliance of quetiapine in the treatment of schizophrenia in children. Methods 79 cases of schizophrenia in children were randomly divided into two groups, treated with quetiapine and risperidone for 8 weeks respectively. The efficacy and adverse reactions were assessed before and at the end of the 2nd, 4th and 8th week with the BPRS and TESS, and were followed up or followed up by telephone for 16 weeks. Results The effective rate of TESS group was 82.50% and the total effective rate was 95.00%. The effective rate of the control group was 82.05% and the total effective rate was 92.30%. There was no significant difference between the two groups (U = 0.16, P > 0.05). Conclusion The efficacy of quetiapine and risperidone in the treatment of schizophrenia in children is similar, while the quetiapine group has better compliance than risperidone group.